Patorno E, et al. - Among type 2 diabetes mellitus (T2D) patients starting empagliflozin vs sitagliptin (a dipeptidyl peptidase-4 inhibitor), researchers assessed the risk of hospitalization for heart failure (HHF) in this first interim analysis from EMPRISE (Empagliflozin Comparative Effectiveness and Safety). A 1:1 propensity score–matched cohort of T2D patients ≥18 years old starting empagliflozin or sitagliptin was found via United States claims data sources; 16,443 patient pairs were identified. Reduced risk of HHF was observed in relation to empagliflozin initiation vs sitagliptin, in patients with T2D as managed in routine care, with and without a history of cardiovascular disease.